Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Me filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron Pharmaceuticals' bid for ...

Me struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, setting ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid. Skip to Main Content. ... Anne Wojcicki, ...

Me, which became a household name for its genetic testing services, is set to emerge from bankruptcy as a nonprofit.

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...